vs

Side-by-side financial comparison of DULUTH HOLDINGS INC. (DLTH) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

DULUTH HOLDINGS INC. is the larger business by last-quarter revenue ($114.9M vs $74.7M, roughly 1.5× Health Catalyst, Inc.). DULUTH HOLDINGS INC. runs the higher net margin — -8.8% vs -121.9%, a 113.1% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -9.6%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-8.9M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -31.6%).

Duluth Holdings Inc., which primarily sells goods through its Duluth Trading Company brand, is an American workwear and accessories company.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

DLTH vs HCAT — Head-to-Head

Bigger by revenue
DLTH
DLTH
1.5× larger
DLTH
$114.9M
$74.7M
HCAT
Growing faster (revenue YoY)
HCAT
HCAT
+3.4% gap
HCAT
-6.2%
-9.6%
DLTH
Higher net margin
DLTH
DLTH
113.1% more per $
DLTH
-8.8%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$18.6M more FCF
HCAT
$9.6M
$-8.9M
DLTH
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-31.6%
DLTH

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DLTH
DLTH
HCAT
HCAT
Revenue
$114.9M
$74.7M
Net Profit
$-10.1M
$-91.0M
Gross Margin
53.8%
Operating Margin
-7.7%
-115.3%
Net Margin
-8.8%
-121.9%
Revenue YoY
-9.6%
-6.2%
Net Profit YoY
64.6%
-340.3%
EPS (diluted)
$-0.29
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLTH
DLTH
HCAT
HCAT
Q4 25
$114.9M
$74.7M
Q3 25
$131.7M
$76.3M
Q2 25
$102.7M
$80.7M
Q1 25
$241.3M
$79.4M
Q4 24
$127.1M
$79.6M
Q3 24
$141.6M
$76.4M
Q2 24
$116.7M
$75.9M
Q1 24
$245.6M
$74.7M
Net Profit
DLTH
DLTH
HCAT
HCAT
Q4 25
$-10.1M
$-91.0M
Q3 25
$1.3M
$-22.2M
Q2 25
$-15.3M
$-41.0M
Q1 25
$-5.6M
$-23.7M
Q4 24
$-28.2M
$-20.7M
Q3 24
$-2.0M
$-14.7M
Q2 24
$-7.9M
$-13.5M
Q1 24
$6.4M
$-20.6M
Gross Margin
DLTH
DLTH
HCAT
HCAT
Q4 25
53.8%
Q3 25
54.7%
52.6%
Q2 25
52.0%
Q1 25
44.1%
Q4 24
52.3%
Q3 24
52.3%
47.5%
Q2 24
52.8%
Q1 24
48.2%
Operating Margin
DLTH
DLTH
HCAT
HCAT
Q4 25
-7.7%
-115.3%
Q3 25
1.8%
-22.9%
Q2 25
-12.0%
-46.0%
Q1 25
-1.8%
-25.4%
Q4 24
-17.4%
-22.0%
Q3 24
-1.1%
-17.9%
Q2 24
-7.7%
-20.8%
Q1 24
3.6%
-30.5%
Net Margin
DLTH
DLTH
HCAT
HCAT
Q4 25
-8.8%
-121.9%
Q3 25
1.0%
-29.1%
Q2 25
-14.9%
-50.8%
Q1 25
-2.3%
-29.9%
Q4 24
-22.2%
-26.0%
Q3 24
-1.4%
-19.3%
Q2 24
-6.7%
-17.8%
Q1 24
2.6%
-27.6%
EPS (diluted)
DLTH
DLTH
HCAT
HCAT
Q4 25
$-0.29
$-1.29
Q3 25
$0.04
$-0.32
Q2 25
$-0.45
$-0.59
Q1 25
$-0.17
$-0.35
Q4 24
$-0.84
$-0.33
Q3 24
$-0.06
$-0.24
Q2 24
$-0.24
$-0.23
Q1 24
$0.20
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLTH
DLTH
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$8.2M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$160.6M
$245.8M
Total Assets
$468.0M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLTH
DLTH
HCAT
HCAT
Q4 25
$8.2M
$95.7M
Q3 25
$5.7M
$91.5M
Q2 25
$8.6M
$97.3M
Q1 25
$3.3M
$342.0M
Q4 24
$9.3M
$392.0M
Q3 24
$9.8M
$387.3M
Q2 24
$6.8M
$308.3M
Q1 24
$32.2M
$327.8M
Total Debt
DLTH
DLTH
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
DLTH
DLTH
HCAT
HCAT
Q4 25
$160.6M
$245.8M
Q3 25
$170.0M
$331.9M
Q2 25
$167.9M
$347.5M
Q1 25
$182.7M
$376.8M
Q4 24
$188.1M
$365.2M
Q3 24
$215.7M
$355.0M
Q2 24
$218.4M
$357.0M
Q1 24
$222.8M
$357.2M
Total Assets
DLTH
DLTH
HCAT
HCAT
Q4 25
$468.0M
$502.6M
Q3 25
$433.8M
$587.1M
Q2 25
$463.7M
$616.2M
Q1 25
$452.4M
$891.5M
Q4 24
$533.1M
$858.9M
Q3 24
$488.6M
$813.0M
Q2 24
$471.4M
$691.7M
Q1 24
$491.2M
$695.1M
Debt / Equity
DLTH
DLTH
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLTH
DLTH
HCAT
HCAT
Operating Cash FlowLast quarter
$-6.7M
$9.9M
Free Cash FlowOCF − Capex
$-8.9M
$9.6M
FCF MarginFCF / Revenue
-7.8%
12.9%
Capex IntensityCapex / Revenue
2.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.7M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLTH
DLTH
HCAT
HCAT
Q4 25
$-6.7M
$9.9M
Q3 25
$32.0M
$-464.0K
Q2 25
$-56.5M
$-9.0M
Q1 25
$41.2M
$280.0K
Q4 24
$-41.1M
$-3.5M
Q3 24
$16.6M
$6.2M
Q2 24
$-33.7M
$1.6M
Q1 24
$69.7M
$10.3M
Free Cash Flow
DLTH
DLTH
HCAT
HCAT
Q4 25
$-8.9M
$9.6M
Q3 25
$29.8M
$-719.0K
Q2 25
$-57.8M
$-9.2M
Q1 25
$38.7M
$-390.0K
Q4 24
$-43.7M
$-3.9M
Q3 24
$15.0M
$5.5M
Q2 24
$-35.2M
$1.3M
Q1 24
$60.6M
$10.1M
FCF Margin
DLTH
DLTH
HCAT
HCAT
Q4 25
-7.8%
12.9%
Q3 25
22.6%
-0.9%
Q2 25
-56.3%
-11.4%
Q1 25
16.0%
-0.5%
Q4 24
-34.4%
-4.9%
Q3 24
10.6%
7.2%
Q2 24
-30.2%
1.7%
Q1 24
24.7%
13.5%
Capex Intensity
DLTH
DLTH
HCAT
HCAT
Q4 25
2.0%
0.4%
Q3 25
1.7%
0.3%
Q2 25
1.3%
0.3%
Q1 25
1.0%
0.8%
Q4 24
2.1%
0.5%
Q3 24
1.2%
0.9%
Q2 24
1.3%
0.4%
Q1 24
3.7%
0.3%
Cash Conversion
DLTH
DLTH
HCAT
HCAT
Q4 25
Q3 25
25.40×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
10.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLTH
DLTH

Sales Channel Directly To Consumer$67.4M59%
Sales Channel Through Intermediary$47.4M41%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons